Roche just made the kind of hard choice that tells you where the whole industry’s head is.
The company is discontinuing acmopatide, a drug that actually succeeded—it hit its main goal in a Phase 2 type 1 diabetes study—in order to concentrate resources on enicepatide for obesity, type 2 diabetes, and cardiovascular disease. Both assets came from Roche’s $2.7 billion acquisition of Carmot Therapeutics. Cutting a winner to focus on the bigger prize is a statement of priorities that could not be more clear. Roche is not interested in a nice type 1 diabetes drug. It wants a shot at the obesity market, and it is willing to kill positive data to sharpen its aim.
That is how gravitational the obesity opportunity has become. When a company with Roche’s resources and scientific heritage axes good data to chase a bigger market, the market it is chasing is the one that matters.
BMS raised its 2026 outlook on strong earnings, but its closely watched Cobenfy Alzheimer’s psychosis data slipped again. Novo faces a shareholder lawsuit over protocol changes in a pivotal CagriSema trial. Capricor walked into its hearing against negative FDA briefing documents. And Celcuity’s Revtorpyk landed a preferred Category 1 spot in the NCCN guidelines just weeks after approval.
Roche Cut a Drug That Worked to Chase the Biggest Market in Medicine
What Happened: Roche is discontinuing acmopatide despite it meeting the main goal of a Phase 2 study in type 1 diabetes, choosing instead to prioritize enicepatide for weight loss, type 2 diabetes, and cardiovascular outcomes. Both drugs came from the $2.7 billion Carmot Therapeutics acquisition.
Why This Decision Matters Beyond Roche
Pharmaceutical companies discontinue drugs all the time. Programs fail, data disappoint, resources get redirected. What is unusual here is that the drug being cut actually worked. Acmopatide hit its Phase 2 endpoint in type 1 diabetes. The data were positive. Roche is not killing it because it failed. Roche is killing it because something else in the portfolio has a bigger commercial ceiling.
That distinction captures the gravitational pull of the obesity market in 2026. Type 1 diabetes is a meaningful condition affecting millions of people. A new therapy that demonstrated Phase 2 efficacy would normally advance into later development. But the obesity opportunity is so large—analysts project it above $150 billion—that Roche made the calculation that concentrating its Carmot portfolio resources on the obesity asset produces a better return than splitting them across both programs.
Enicepatide is a dual mechanism drug targeting GLP 1 and another metabolic pathway, positioning it in the same competitive space as Lilly’s tirzepatide (GIP/GLP 1) and retatrutide (GIP/GLP 1/glucagon). For Roche to credibly compete in that space, it needs to move fast, generate differentiated data, and build the manufacturing and commercial infrastructure to support a launch against the two most capable incumbents in the industry. Concentrating resources on enicepatide rather than splitting them with acmopatide is the first step in that strategy.
The Challengers Are Mobilizing
Roche is not the only company making aggressive moves to compete with Lilly in obesity. The field is filling out:
Novo Nordisk created the GLP 1 category with semaglutide and is defending its position with oral and injectable Wegovy, the MASH approval, CagriSema (despite the litigation cloud), and the legal fight against Lilly’s advertising. Novo has the scale and the prescriber relationships, but Lilly’s tirzepatide and retatrutide have set an efficacy bar that semaglutide cannot match.
Arrowhead teased last Friday that its ARO INHBE, an RNA interference approach, showed roughly double the weight loss of tirzepatide in a small interim readout. The data are very preliminary, but RNA interference represents a fundamentally different modality that works through different biology than the peptide agonists that dominate today.
Pfizer reshuffled its obesity discovery leadership after danuglipron’s repeated failures, but remains far behind and would likely need to acquire its way into the category rather than build from scratch.
Amgen has MariTide, its own next generation approach. Multiple other companies are advancing amylin combinations, muscle preserving agents, and novel targets.
The question we set for the week: can the second wave of obesity science, novel mechanisms and focused bets from well capitalized players, actually dent Lilly’s dominance? Our read remains that Lilly leads the present decisively with tirzepatide, retatrutide, and Foundayo spanning the efficacy and convenience spectrum. Three positive pivotal trials for retatrutide. The highest weight loss ever demonstrated in Phase 3. A three tier portfolio no competitor can match. That lead holds for the current generation of drugs and likely through the next two to three years.
But the challengers are no longer theoretical. Roche concentrating its firepower. Arrowhead showing early signals from different biology. Novo fighting on every front. The obesity market is so large that it will attract relentless investment, and the mechanism that eventually challenges Lilly may come from an entirely different direction than the peptide agonists that dominate today. Watch the next generation data, because that is where a genuine threat, if one comes, will originate.
Our Pro brief maps the challengers to Lilly and assesses which have a credible path to closing the gap. [Details below.]
BMS Raised Its Outlook, But the Alzheimer’s Data Everyone Wanted Slipped Again
What Happened: Strong quarterly results prompted BMS to lift its 2026 outlook, but the company faces another delay for its Cobenfy Alzheimer’s psychosis data and a pushed back readout for milvexian.
The Karuna Thesis Stays Unproven
We have tracked the Cobenfy (formerly KarXT) Alzheimer’s psychosis readout as one of the summer’s key binary events—the clearest test of whether BMS’s roughly $14 billion Karuna acquisition pays off. It keeps slipping.
Cobenfy is a muscarinic receptor agonist that represents a genuinely new mechanism in neuropsychiatry. It is already approved and selling in schizophrenia, which is commercially meaningful. But the $14 billion acquisition price was justified by the expansion opportunity—the belief that the mechanism would work across multiple neuropsychiatric conditions, starting with Alzheimer’s psychosis, a condition where tens of thousands of patients experience hallucinations, delusions, and agitation with almost no good treatment options.
Each delay pushes out the moment when BMS can prove the Karuna price was justified. It extends investor uncertainty. It gives competitors more time. And in neuropsychiatry, where the base rate of success is low and the history of disappointment is long, a delayed readout carries an implicit anxiety that the data might not be what the company hopes.
The strong earnings and raised guidance show that BMS’s base business is performing well enough to fund its future while it waits. That matters. The company is not in financial distress. But the growth narrative increasingly depends on Cobenfy’s expansion beyond schizophrenia, and until the Alzheimer’s data arrive and read out positive, the most important question about BMS’s future remains unanswered.
Regeneron and Takeda also reported, both beating expectations, capping an earnings season that broadly confirmed the sector’s health. The Q2 picture is now clear: the industry is genuinely healthier than it has been in years, the recovery is real, and the numbers backed the mood. The blemishes are in pipelines, not in base businesses—individual programs hitting timing snags even as the companies funding them post strong quarters.
Novo Faces a Shareholder Lawsuit Over CagriSema
What Happened: Novo Nordisk faces a shareholder lawsuit alleging it withheld information about crucial protocol changes in a Phase 3 study of CagriSema, its combination weight loss drug, which the plaintiffs say led investors to buy shares at artificially inflated prices.
The Pressure on Novo Keeps Building
CagriSema, the combination of semaglutide and cagrilintide, was meant to be a centerpiece of Novo’s next generation obesity strategy—the drug that would close the efficacy gap with Lilly’s tirzepatide by combining two mechanisms. A lawsuit alleging the company hid important information about how it conducted the pivotal trial is not just a legal risk. It is a narrative risk. It adds to a stretch that includes:
The advertising lawsuit against Lilly, where Novo sued over what it calls misleading GLP 1 advertising and then escalated by seeking an injunction to halt the ads.
The efficacy gap with Lilly, where semaglutide at 15 to 17% weight loss trails tirzepatide at approximately 22% and retatrutide at 28.3%.
The CagriSema Phase 3 miss earlier this year that disappointed on the headline weight loss number.
And now a shareholder suit alleging undisclosed protocol changes in the CagriSema trial.
The contrast with Lilly, which is executing cleanly across fifteen deals, three positive retatrutide pivotal trials, and the broadest metabolic franchise in the industry, keeps getting sharper. Novo created the GLP 1 category. It still commands enormous market share and has deep commercial infrastructure. But the accumulation of competitive pressure, legal conflict, and trial controversy is weighing on the company at a moment when it needs to project confidence and momentum.
Capricor Walked Into Its Hearing Already Behind
What Happened: The FDA issued negative briefing documents on Capricor’s deramiocel for Duchenne muscular dystrophy cardiomyopathy ahead of its advisory committee meeting.
The Trajectory Has Been Downhill Since June
We have tracked this story through a sequence that has gone from concerning to adverse:
June: The FDA surprised everyone by calling an advisory committee for deramiocel, a drug it had already rejected once. CEO Linda Marbán said the FDA had not communicated any concerns about the resubmission.
Late July: FDA reviewers published briefing documents questioning whether the filing shows substantial evidence of effectiveness.
This week: Capricor entered its hearing against those negative documents, facing a panel primed by the agency’s own skepticism.
For Duchenne cardiomyopathy patients—people with the cardiac complications that are a leading cause of death in Duchenne muscular dystrophy—the stakes are personal and urgent. There are no approved therapies specifically targeting the cardiac damage the disease causes. Deramiocel was designed to address that gap. But the FDA’s own staff have questioned whether the data support approval, and walking into an advisory committee against that kind of briefing is genuinely difficult.
The August 22 PDUFA date now carries more risk than at any point since the filing was accepted. A negative advisory committee vote, if it comes, would not formally prevent approval (the FDA can overrule its advisers), but it would make approval substantially harder to justify and would create political risk for an agency already operating without permanent leadership.
Amgen Mounted Its Tavneos Defense
What Happened: Amgen launched an official defense of Tavneos, pushing back as it fights to keep the rare disease drug on the market.
Where This Stands: The Tavneos saga has been one of the most dramatic post market stories of the year. The sequence: FDA scrutiny beginning in January. The agency asking Amgen to voluntarily pull the drug over patient deaths in June. Amgen commissioning an independent Duke analysis to defend it. The European CHMP recommending revocation of marketing authorization. A leading medical journal retracting the pivotal study. And now Amgen launching a formal defense.
Each step has compounded the last. Defending a drug against a safety signal is difficult. Defending it after the pivotal study has been retracted is much harder. Amgen is not giving up the franchise—Tavneos treats ANCA associated vasculitis, a serious autoimmune condition where patients genuinely need steroid sparing options—but the company is defending against the weight of regulatory, academic, and safety evidence that has accumulated throughout the year. The odds remain long, but the clinical need for the patients who depend on the drug is real, and that is the argument Amgen is making.
Celcuity Turned Its Approval Into a Guideline Win in Weeks
What Happened: Celcuity said Revtorpyk (gedatolisib) was added to the NCCN guidelines as a preferred Category 1 second line and later therapy for the breast cancer patients it treats.
Why Guideline Inclusion This Fast Matters
In oncology, the NCCN guidelines are the reference that community and academic oncologists use to make treatment decisions and that payers use to determine coverage. A drug’s placement in these guidelines heavily influences whether it gets prescribed and reimbursed. Preferred Category 1 status is the highest level, reflecting high level evidence and uniform expert consensus. It tells every oncologist that this is a recommended standard option.
Getting there within weeks of a first ever FDA approval is unusually fast and commercially significant. Most newly approved drugs spend months building awareness, accumulating real world experience, and working through the payer coverage process before guideline committees evaluate them. Celcuity accelerated through that sequence, and the speed suggests the guideline committee was convinced by the clinical data and the wild type PIK3CA positioning we highlighted at approval.
For a company landing its first commercial product, preferred guideline status this early accelerates the revenue ramp dramatically. Rather than spending quarters building physician awareness from scratch, Revtorpyk arrives with the institutional endorsement that drives both prescribing and reimbursement. The drug that dropped 25% on its initial data readout in June, then won FDA approval in July, now has the strongest possible guideline backing in August. The trajectory from rocky data reception to approved and guideline endorsed is one of the sharper commercial recovery stories of the year.
Quick Hits
J&J signed a collaboration with Sail Biosciences that includes an option to acquire the company, adding an early stage asset to its pipeline. J&J has been selectively active on the deal front even as its Q2 oncology results disappointed, suggesting the company sees its pipeline gaps clearly and is working to fill them.
The U.S. is releasing $600 million in funding for Gavi, the global vaccine alliance, ending months of uncertainty over Washington’s support. The funding was held up amid a dispute over vaccine safety and purchasing priorities. For the global immunization landscape, the release restores a critical source of financing for vaccine procurement in low and middle income countries.
MapLight Therapeutics lost about two thirds of its market value even after reporting positive mid stage results, a reaction so harsh that an analyst pushed back, citing the totality of the data as more supportive than the stock move suggested. The disconnect between clinical results and stock performance—which we also saw with Celcuity in June before it rebounded—is a reminder that market reactions on the day of a readout can overshoot in either direction.
GSK recorded $2.4 billion in impairment charges for the quarter, roughly the same amount its new restructuring aims to save annually. The symmetry is coincidental but illustrative: GSK is writing down the value of past bets at the same scale it is cutting costs to fund future ones. It frames the magnitude of the reset we have tracked under Luke Miels this year.
Strategic Themes
1. Roche Cutting a Positive Drug to Chase Obesity Tells You How Large the Prize Has Become
When a company with Roche’s resources kills a drug that worked in order to concentrate on obesity, the market being chased is the one that defines the era. Obesity is pulling resources away from other therapeutic areas not because those areas lack merit but because the commercial ceiling in obesity is so high that anything smaller looks like a distraction. That gravitational pull will continue to shape portfolio decisions across the industry for years.
2. BMS’s Cobenfy Delay Keeps the Biggest Question About the Company Unanswered
Strong earnings. Raised guidance. A healthy base business. But the $14 billion Karuna acquisition was a bet on expansion into Alzheimer’s psychosis and other neuropsychiatric conditions, and the data keep slipping. Until the readout arrives, the thesis that justified the premium remains unproven. The base business buys time. It does not substitute for the pipeline delivering.
3. Novo Is Fighting on Too Many Fronts Simultaneously
Suing Lilly over advertising. Getting sued by shareholders over CagriSema. Trailing on efficacy. Watching the MASH approval generate excitement while Lilly’s retatrutide generates three pivotal wins. The competitive pressure, the legal conflicts, and the trial controversies are accumulating in a way that tests even a company of Novo’s scale. The contrast with Lilly’s clean execution is becoming the defining narrative of the GLP 1 competition.
4. Celcuity’s Speed from Approval to Preferred Guideline Is the Template for a Strong Launch
First FDA approval in July. Preferred Category 1 NCCN guideline status in August. The fastest possible commercial ramp for a drug that had a rocky data reception just two months ago. Guideline inclusion at this level and this speed de risks the launch and validates the clinical positioning. For other companies planning first commercial launches, Celcuity’s trajectory shows what is possible when the data, the positioning, and the guideline timing align.
Frequently Asked Questions
Why did Roche cut acmopatide?
To concentrate resources on enicepatide for obesity, type 2 diabetes, and cardiovascular disease. Acmopatide hit its Phase 2 goal in type 1 diabetes but Roche decided the obesity opportunity was larger. Both came from the $2.7B Carmot acquisition.
What happened with BMS’s Cobenfy data?
The Alzheimer’s psychosis readout for Cobenfy (formerly KarXT) slipped again. BMS raised its 2026 outlook on strong base business performance, but the expansion data that would validate the $14B Karuna acquisition keeps getting delayed. The milvexian readout was also pushed back.
What is the Novo lawsuit?
Shareholders allege Novo withheld information about protocol changes in a Phase 3 CagriSema trial, leading investors to buy at inflated prices. It adds to Novo’s ongoing advertising lawsuit against Lilly and the competitive pressure of trailing on efficacy.
How did Capricor’s hearing go?
Capricor entered against negative FDA briefing documents questioning substantial evidence of effectiveness. The August 22 PDUFA date now carries significant risk. We have tracked the downhill trajectory since the surprise adcomm announcement in June.
What is Celcuity’s guideline status?
Revtorpyk (gedatolisib) was added to the NCCN guidelines as preferred Category 1 for second line and later treatment of its breast cancer population. The fastest possible guideline inclusion for a newly approved drug, accelerating the commercial ramp.
Is Amgen still defending Tavneos?
Yes. Amgen launched a formal defense despite the FDA’s voluntary removal request, the CHMP revocation recommendation, and the retraction of the pivotal study. The company argues the clinical need for ANCA vasculitis patients justifies continued access.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
The Challengers to Lilly, Ranked. We map who can credibly compete in obesity—Novo on scale, Roche on focus, Arrowhead on biology—and assess whether any of them can close the gap within the next two to three years or whether the real threat comes from the next generation mechanisms still in early trials.
BMS’s Cobenfy Delay Keeps the Karuna Thesis Unproven. We analyze what repeated readout slips mean for the $14B acquisition, assess the gap between a healthy base business and an unproven growth thesis, and evaluate how long BMS can defer the verdict before it costs the stock.
Celcuity Went from Approval to Preferred Guideline in Weeks. We assess what preferred Category 1 NCCN status does to the commercial trajectory, model the revenue ramp acceleration, and evaluate whether the June stock drop now looks like the market focusing on the wrong number.
Plus: Roche Carmot portfolio prioritization, Novo CagriSema lawsuit implications, Capricor adcomm trajectory, Amgen Tavneos defense assessment, GSK $2.4B impairment context, MapLight overcorrection, and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
